Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-GENE trial
2023-507029-40-00Phase 3Authorised
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Aug 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Candesartan with Placebo (2 arms). Primary endpoint: Composite progression in LV function or volume. Planned start Aug 2023; status: authorised.
02
Drugs
candesartan
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2023-507029-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507029-40-00.